Rapp Alexandra R, Ogunbileje John O, Djouodo-Nemzou Diane, Okorodudu Anthony O
Department of Pathology, University of Texas Medical Branch at Galveston, 301 University Blvd., Galveston, TX 77555, United States.
Department of Pathology, University of Texas Medical Branch at Galveston, 301 University Blvd., Galveston, TX 77555, United States.
Clin Chim Acta. 2021 Aug;519:140-141. doi: 10.1016/j.cca.2021.04.009. Epub 2021 Apr 17.
Individuals who have been vaccinated for COVID19 should have IgG antibody in response to the specific antigen that is the target in the vaccine development. There are several options for targeted COVID19 antigen, but most manufacturers have focused on the spike protein. Using our understanding of the targeted antigen for vaccine development, we can develop testing algorithmic scheme for anti-spike and anti-nucleocapsid antibody assays to aid delineation of infection versus vaccination in our patient population. Clear communication from laboratories specifying the specific SARS-CoV-2 antibodies (i.e., anti-spike, anti-nucleocapsid, or both) in their antibody tests at both the ordering and reporting levels will play crucial role in the development of this approach and is essential to avoid potential provider/patient confusion in the interpretation of serologic testing.
接种过新冠病毒疫苗的个体应具有针对疫苗研发中特定抗原的IgG抗体。针对新冠病毒抗原的选择有多种，但大多数制造商都聚焦于刺突蛋白。利用我们对疫苗研发中靶向抗原的理解，我们可以开发针对抗刺突和抗核衣壳抗体检测的测试算法方案，以帮助区分我们患者群体中的感染与接种情况。实验室在订购和报告层面明确说明其抗体检测中特定的严重急性呼吸综合征冠状病毒2抗体（即抗刺突、抗核衣壳或两者），这将在该方法的开发中发挥关键作用，对于避免临床医生/患者在血清学检测结果解读中可能出现的混淆至关重要。
